ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
Metrics: PDF 1394 views | HTML 3312 views | ?
Shanchun Guo1,2, Changde Zhang1,2, Melyssa Bratton2,3, Madhusoodanan Mottamal1,2, Jiawang Liu1,2, Peng Ma2,3, Shilong Zheng1,2, Qiu Zhong1,2, Lin Yang4, Thomas E. Wiese2,3, Yong Wu5, Matthew J. Ellis6, Margarite Matossian7, Matthew E. Burow7, Lucio Miele8, René Houtman9 and Guangdi Wang1,2
1Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA
2RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA
3College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA
4College of Pharmacy Chongqing Medical and Pharmaceutical College, University Town, Chongqing, 401331, China
5Department of Internal Medicine, Charles Drew University, Los Angeles, CA 90059, USA
6Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
7Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
8Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
9Nuclear Receptor Group, PamGene International, 5211HH Den Bosch, The Netherlands
Guangdi Wang, email: email@example.com
Keywords: steroidal oral SERD; breast cancer; estrogen receptor mutant; Y537S; bioavailability
Received: October 12, 2017 Accepted: December 27, 2017 Published: January 08, 2018
Advances in oral SERDs development so far have been confined to nonsteroidal molecules such as those containing a cinnamic acid moiety, which are in earlystage clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD structurally analogous to fulvestrant. In this study, we examined the binding details of ZB716 to the estrogen receptor alpha (ERα) by computer modeling to reveal its interactions with the ligand binding domain as a steroidal molecule. We also found that ZB716 modulates ERα-coregulator interactions in nearly identical manner to fulvestrant. The ability of ZB716 to inhibit cell growth and downregulate ER expression in endocrine resistant, ERα mutant breast cancer cells was demonstrated. Moreover, in both the MCF-7 xenograft and a patient derived xenograft model, orally administered ZB716 showed superior efficacy in blocking tumor growth when compared to fulvestrant. Importantly, such enhanced efficacy of ZB716 was shown to be attributable to its markedly higher bioavailability, as evidenced in the final plasma and tumor tissue concentrations of ZB716 in mice where drug concentrations were found significantly higher than in the fulvestrant treatment group.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.